New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 18, 2014
06:58 EDTGS, MDT, COV, C, JPMMedtronic, Covidien using just two advisers for deal, NY Times says
Medtronic (MDT) and Covidien (COV) hired just one financial adviser each for Medtronic's takeover of Covidien, with Covidien choosing Goldman Sach (GS) and Medtronic tapping Perella Weinberg, according to the New York Times. Companies involved in large M&A deals often hire many more advisers, the newspaper noted. Other banks that offer M&A advisory services include Citigroup (C) and JPMorgan (JPM). Reference Link
News For GS;MDT;COV;C;JPM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 19, 2014
07:17 EDTCCitigroup up against hard situation in Argentina bond plea, Reuters says
Subscribe for More Information
September 18, 2014
14:08 EDTC, GS, JPMBanks look to high-interest personal loans to boost revenue, WSJ says
Subscribe for More Information
12:18 EDTMDTNY AG announces national settlement with Medtronic for Medicaid violations
Attorney General Eric T. Schneiderman announced that 46 states and the District of Columbia have reach a settlement agreement with Minnesota-based company Medtronic to resolve claims under the False Claims Act that Medtronic improperly induced physicians to recommend Medtronic devices to treat cardiac rhythmic disease. New York led a national team composed of members from Oregon, Texas and California to negotiate the settlement. The federal government settled its matter in May of this year...The agreement requires Medtronic to pay the settling states $362,362, which will go to those states’ Medicaid programs. The matter was brought by a whistleblower, Adolfo Schroeder, and was filed in U.S. District Court for the Eastern District of California. The Attorney General would like to thank Mr. Schroeder for bringing this matter to the government’s attention. Under the terms of the agreement, the New York Medicaid Program will receive $67,369.31. Reference Link
05:31 EDTJPMVisa to undertake assessment of stake in Monitise
Visa (V) and Monitise entered into an alliance agreement in 2009. At the same time, Visa began investing in Monitise. Given the maturation of Monitise as a company, Visa is considering its options with respect to the investment and has engaged J.P. Morgan Securities (JPM) to assist. Visa will also be lessening its dependence on external mobile development resources. In 2009, in conjunction with its commercial partnership, Visa invested in Monitise as a 14.4% owner of the company in order to provide capital support to a leader in the evolution of the mobile payments sector. Over time, Visa’s holdings have been reduced to its current 5.5% stake in the company. This reduction in ownership and associated influence is consistent with Visa’s investment practice to seed emerging players and, over time, taper that influence as the partner company grows. Under their agreement, Monitise will provide Visa with mobile platform development services through 2016. As both Visa and the payments industry evolve at a rapid pace, Visa intends to continue increasing its investment in its own in-house capabilities and, as a result, reducing its use of external resources.
September 17, 2014
16:01 EDTCOVCovidien raises quarterly dividend to 36c from 32c
Subscribe for More Information
13:51 EDTJPMJPMorgan to replace some credit cards following Home Depot breach, Reuters says
Subscribe for More Information
13:16 EDTJPM, C, GSHolder says DOJ looking to charge bank executives, Washington Post says
Subscribe for More Information
09:08 EDTMDTMedtronic launches new Balloon Kyphoplasty Platform
Subscribe for More Information
07:43 EDTMDTBofA/Merrill to hold a conference
Subscribe for More Information
07:37 EDTJPMMorningstar to hold a conference
Subscribe for More Information
06:54 EDTJPMNY Attorney General announces NYC bank identity-theft ring takedown
Subscribe for More Information
06:09 EDTMDTIntegra LifeSciences to acquire Medtronic instrumentation lines for $60M
Integra LifeSciences (IART) and Medtronic (MDT) announced an agreement in which Integra will acquire Medtronic's MicroFrance and Xomed manual ENT and laparoscopy instrumentation lines for approximately $60M in cash. Integra expects the transaction to close in Q4. Integra will acquire a portfolio of approximately 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments, as well as the St. Aubin le Monial, France manufacturing facility. Sales from the products being acquired totaled approximately $30M, two-thirds of which were generated outside the U.S. Integra expects to record approximately $27M-$30M in revenue and approximately 10c of adjusted EPS in calendar 2015 from this acquisition. The earnings accretion should rise after the first year once certain sales transitions are complete. The company expects the acquisition to contribute less than $5M in revenue and be neutral to earnings in Q4. The transition and integration is expected to be completed by 2H15.
September 16, 2014
14:44 EDTC, GS, JPMVirginia AG files $1.15B lawsuit against banks that sold RMBS during crisis
Subscribe for More Information
11:51 EDTCOV, MDTOECD looks to close tax loopholes with new proposals
Subscribe for More Information
10:22 EDTJPMBanks set for ad battle to be default choice for Apple Pay, Apple Insider says
Subscribe for More Information
08:07 EDTMDTMedtronic drug-coated baloon shows strong clinical, economic benefit
Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics, or TCT, conference, the latest clinical and economic data on the IN.PACT Admiral drug-coated balloon, or DCB, from Medtronic augments an already robust body of evidence that continues to drive a reconsideration of the standard of care for peripheral artery disease, or PAD, in leg arteries above the knee. The IN.PACT Admiral DCB remains an investigational medical device in the United States. No drug-coated balloon has yet received approval from the FDA. The new data come from the real-world IN.PACT Global study, the largest and most rigorous post-market evaluation of its kind for any peripheral artery intervention, and from an ongoing economic outcomes analysis of the U.S. phase of the landmark IN.PACT SFA trial. Together, the results show that the IN.PACT Admiral DCB is not only clinically superior, but also cost-effective for the treatment of atherosclerotic lesions in the superficial femoral artery, or SFA, or proximal popliteal artery, or PPA, at 12 months compared to standard percutaneous transluminal angioplasty, or PTA.
07:51 EDTGSGoldman Sachs-led investor group backs Privia Health for national expansion
Subscribe for More Information
07:31 EDTMDTEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
07:19 EDTGSCompanies' share buybacks at fasttest clip since 2007, WSJ reports
Companies are buying back their own shares at its fastest pace since the financial crisis to fuel a stock rally, reports the Wall Street Journal. According to Birinyi Associates, companies have bought back $338.3B of stock in 1H14, the most since 2007. Citing an analysis by Barclays, companies with the largest buyback programs by dollar value have outperformed the broader market by 20% since 2008. Reference Link
06:32 EDTCSpringleaf could be potential bidder for Citigroup's OneMain unit, WSJ reports
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use